Patents Assigned to Cephalon, Inc.
  • Thienopyrimidine Inhibitors of Atypical Protein Kinase C
    Publication number: 20140323435
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: May 22, 2014
    Publication date: October 30, 2014
    Applicants: Cancer Research Technology Limited, Cephalon, Inc.
    Inventors: Bruce D. Dorsey, Keith S. Learn, Emma L. Morris, Gregory R. Ott, Jonathan R.A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • Pharmaceutical formulations of modafinil
    Patent number: 8859621
    Abstract: Compositions of modafinil and methods of treating neurologically related conditions with the administration of modafinil. Also compositions that include modafinil and one or more excipients such as diluents, disintegrants, binders and lubricants.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: October 14, 2014
    Assignee: Cephalon, Inc.
    Inventors: Craig S. Heacock, Alpa B. Parikh, Piyush R. Patel
  • SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS
    Publication number: 20140296212
    Abstract: The present invention provides compounds of formula I: their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceutical compositions thereof.
    Type: Application
    Filed: February 10, 2014
    Publication date: October 2, 2014
    Applicant: CEPHALON, INC.
    Inventors: Edward R. Bacon, Thomas R. Bailey, Sankar Chatterjee, Derek Dunn, Greg A. Hostetler, Robert L. Hudkins, Allison L. Zulli, Brigitte Lesur, Babu G. Sundar, Christophe Yue
  • URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS
    Publication number: 20140275077
    Abstract: The present application provides compounds of Formula I or salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c, Y, R3, X, E and G are as defined herein, compositions, methods of treatment and uses thereof.
    Type: Application
    Filed: May 13, 2014
    Publication date: September 18, 2014
    Applicant: Cephalon, Inc.
    Inventors: Reddeppa Reddy Dandu, Robert L. Hudkins, Kurt A. Josef, Catherine P. Prouty, Rabindranath Tripathy
  • Solid State Forms of 6-[4-[3-((R)-2-Methylpyrrolidine-1-yl)-propoxy]phenyl] 2H-pyridazine-3-one Hydrochloride
    Publication number: 20140275102
    Abstract: Solid state forms of the compound 6-[4-[3-((R)-2-methylpyrrolidine-1-yl)-propoxy]phenyl]2H-pyridazine-3-one hydrochloride (Compound 1), processes for preparing the solid state forms, and pharmaceutical compositions thereof, are provided. Compound 1 is a histamine H3 receptor antagonist/inverse agonist. Thus the provided solid state forms are useful, for example, for the manufacture of a medicament for the treatment of disorders mediated by the H3 receptor.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: CEPHALON, INC.
    Inventors: Stephen J. Bierlmaier, Laurent Courvoisier, Ralph C. Haltiwanger, Martin J. Jacobs
  • Modafinil compositions
    Patent number: 8809586
    Abstract: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: August 19, 2014
    Assignee: Cephalon, Inc.
    Inventors: Magali Bourghol Hickey, Matthew Peterson, Orn Almarsson, Mark Oliveira
  • Sublingual buccal effervescent
    Patent number: 8802130
    Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: August 12, 2014
    Assignee: Cephalon, Inc.
    Inventors: S. Indiran Pather, Rajendra K. Khankari, Jonathan D. Eichman, Joseph R. Robinson, John Hontz
  • Bendamustine pharmaceutical compositions
    Patent number: 8791270
    Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: July 29, 2014
    Assignee: Cephalon, Inc.
    Inventors: Jason Edward Brittain, Joe Craig Franklin
  • Liquid Formulations Of Bendamustine
    Publication number: 20140206733
    Abstract: Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.
    Type: Application
    Filed: March 21, 2014
    Publication date: July 24, 2014
    Applicant: Cephalon, Inc.
    Inventors: Anthony S. Drager, Rachel Y. Labell, Piyush R. Patel
  • Lyophilization cakes of proteasome inhibitors
    Patent number: 8785418
    Abstract: Lyophilized cakes of proteasome inhibitors are described, as well as methods for their production and use.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: July 22, 2014
    Assignee: Cephalon, Inc.
    Inventors: Denis Bricout, Helene Cambourieux, Michael L. Cappola, Nicole Frati, Piyush R. Patel
  • Novel Solid Forms Of Bendamustine Hydrochloride
    Publication number: 20140187598
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Application
    Filed: March 7, 2014
    Publication date: July 3, 2014
    Applicant: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Combination therapy for the treatment of multiple myeloma
    Patent number: 8765720
    Abstract: The present invention provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and bortezomib. The invention further provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and melphalan.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: July 1, 2014
    Assignee: Cephalon, Inc.
    Inventor: James R. Berenson
  • Tumor necrosis factor inhibitors
    Patent number: 8765810
    Abstract: The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-? mediated conditions.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: July 1, 2014
    Assignees: The Trustees Of The University Of Pennsylvania, Cephalon, Inc.
    Inventors: Mark I. Greene, Ramachandran Murali, Xin Cheng, Raphael Ottenbrite, Yingxin Xiaio
  • Transmucosal effervescent
    Patent number: 8765100
    Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of additional pH adjusting substance in combination with the effervescent for promoting the absorption of drugs is also disclosed.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: July 1, 2014
    Assignee: Cephalon, Inc.
    Inventors: Jonathan D. Eichman, John Hontz, Rajendra K. Khankari, Sathasivan Indiran Pather, Joseph R. Robinson
  • Tricyclic derivatives and their pharmaceutical use and compositions
    Patent number: 8765779
    Abstract: This application relates to tricyclic compounds of Formula I: including all stereoisomers, mixtures of stereoisomers, and salts thereof. This application also relates to compositions comprising compounds of Formula I and uses therefore.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: July 1, 2014
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Thomas R. Bailey, Derek D. Dunn, Greg A. Hostetler, Robert J. McHugh, George C. Morton, Gerard C. Rosse, Joseph M. Salvino, Babu G. Sundar, Rabindranath Tripathy
  • Sublingual buccal effervescent
    Patent number: 8753611
    Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: June 17, 2014
    Assignee: Cephalon, Inc.
    Inventors: Jonathan D. Eichman, John Hontz, Rajendra K. Khankari, Sathasivan Indiran Pather, Joseph R. Robinson
  • BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
    Publication number: 20140148490
    Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 29, 2014
    Applicant: Cephalon, Inc.
    Inventors: Jason Edward Brittain, Joe Craig Franklin
  • PYRIDAZINONE DERIVATIVES
    Publication number: 20140142088
    Abstract: The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition.
    Type: Application
    Filed: November 18, 2013
    Publication date: May 22, 2014
    Applicant: CEPHALON, INC.
    Inventors: Edward R. Bacon, Thomas R. Bailey, Nadine C. Becknell, Sankar Chatterjee, Derek Dunn, Greg A. Hostetler, Robert L. Hudkins, Kurt A. Josef, Lars J.S. Knutsen, Ming Tao, Alison L. Zulli
  • Sublingual buccal effervescent
    Patent number: 8728441
    Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: May 20, 2014
    Assignee: Cephalon, Inc.
    Inventors: Jonathan D. Eichman, John Hontz, Rajendra K. Khankari, Sathasivan Indiran Pather, Joseph R. Robinson
  • Crystalline forms of a pharmaceutical compound
    Patent number: 8729065
    Abstract: Described are crystalline forms of the pharmaceutical compound “[9S-(9?,10?,12?)]-5,16-Bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3?,2?,1?-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester”, as well as methods for their use and preparation.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: May 20, 2014
    Assignee: Cephalon, Inc.
    Inventors: Michael Harold Rock, Heidi Lopez De Diego, Kim Lasse Christensen, Ole Nielsen, Anders Buur, Mark Howells